AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,494.00p
   
  • Change Today:
      94.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,667.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.62m
  • Volume: 143,692
  • Market Cap: £162,722m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 2.2% 0.0%
Div Cover 2.6 2.8
Op Mrgn 18.5% 30.4%
ROCE 60.7%  
Latest F'cast
P/E 16.9 15.0
PEG 1.3 1.6
Pr/Revenue 4.0 2.8
Pr/Book 5.3  
Latest F'cast
Revenue 18.0% -20.5%
PBT 26.0% 50.3%
EPS 13.1% 9.2%
DPS 6.9% n/a

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 26,617.00 3,916.00 244.00¢ 40.1 0.3 +137% 280.00¢ 2.9%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,448.2 n/a -97% 287.00¢ 2.5%
31-Dec-22 44,351.00 2,501.00 212.00¢ 70.6 0.0 +2,550% 290.00¢ 1.9%
31-Dec-23 45,811.00 6,899.00 726.00¢ 19.5 0.1 +242% 290.00¢ 2.0%
31-Dec-24 54,073.00 8,691.00 821.00¢ 17.0 1.3 +13% 310.00¢ 2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 57,362.19 17,436.02 673.88p 15.4 1.7 +9% 244.57p 0.0%
31-Dec-26 60,816.34 19,565.21 764.11p 13.6 1.0 +13% 256.16p 0.0%
31-Dec-27 64,248.51 21,576.92 839.13p 12.4 1.3 +10% 263.29p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Enhertu combination improved PFS in 1L HER2+ mBC 22-Apr-2025 07:00 RNS
Result of AGM 11-Apr-2025 17:30 RNS
Imfinzi approved in EU for AEGEAN 04-Apr-2025 07:05 RNS

AstraZeneca ShareCast News

AstraZeneca receives positive Phase III trial re... 22-Apr-2025 ShareCast
London close: Stocks fall as China retaliates to... 09-Apr-2025 ShareCast
AstraZeneca's Enhertu gets further EU approval 04-Apr-2025 ShareCast

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,494.00p
Change Today 94.00p
% Change 0.90 %
52 Week High 13,276.00p
52 Week Low 9,667.00p
Volume 143,692
Shares Issued 1,550.62m
Market Cap £162,722m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.47% below the market average94.47% below the market average94.47% below the market average94.47% below the market average94.47% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Price Trend
28.14% below the market average28.14% below the market average28.14% below the market average28.14% below the market average28.14% below the market average
29.17% above the sector average29.17% above the sector average29.17% above the sector average29.17% above the sector average29.17% above the sector average
Income
64.53% below the market average64.53% below the market average64.53% below the market average64.53% below the market average64.53% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
85.89% above the market average85.89% above the market average85.89% above the market average85.89% above the market average85.89% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 14
Neutral 4
Sell 0
Strong Sell 1
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 28-Apr-2025

Time Volume / Share Price
10:42 1 @ 10,496.00p
10:42 91 @ 10,494.91p
10:42 8 @ 10,495.48p
10:42 0 @ 10,496.00p
10:42 63 @ 10,494.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page